Abstract OT1-1-06: A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps102 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS102-TPS102 ◽

Cited By ~ 15

Author(s):

P. A. Ellis ◽

C. H. Barrios ◽

Y. Im ◽

M. Patre ◽

F. Branle ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)

10.1158/1538-7445.am2020-ct212 ◽

2020 ◽

Author(s):

John Crown ◽

William Jacot ◽

Denis M. Collins ◽

Linda Coate ◽

Anna Saetersdal ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1128881.585979 ◽

2008 ◽

Author(s):

Carmelo Bengala

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer.

10.1158/0008-5472.sabcs-3132 ◽

2009 ◽

Cited By ~ 3

Author(s):

K Najagami ◽

K Inoue ◽

M Mizutani ◽

Y Hozumi ◽

Y Fujiwara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase Iii Study ◽

Trastuzumab Monotherapy ◽

Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90842-7 ◽

2004 ◽

Vol 2 (3) ◽

pp. 125-126 ◽

Cited By ~ 20

Author(s):

J.M Extra ◽

F Cognetti ◽

D Maranichi ◽

R Snyder ◽

L Mauriac ◽

...

Keyword(s):

Breast Cancer ◽

Multicentre Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial.

10.1158/0008-5472.sabcs-09-4094 ◽

2009 ◽

Cited By ~ 6

Author(s):

J. Huober ◽

P. Fasching ◽

S. Paepke ◽

E. Kubista ◽

M. Barsoum ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer

10.1158/0008-5472.sabcs13-p2-16-10 ◽

2013 ◽

Author(s):

EA Perez ◽

JM López-Vega ◽

L Del Mastro ◽

T Petit ◽

C Zamagni ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

Medical Oncology ◽

10.1007/s12032-010-9754-2 ◽

2010 ◽

Vol 28 (S1) ◽

pp. 142-151 ◽

Cited By ~ 3

Author(s):

M. Ghosn ◽

P. Aftimos ◽

F. S. Farhat ◽

J. G. Kattan ◽

C. Hanna ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Weekly Docetaxel ◽

Her 2 ◽

Phase III study of liposome-encapsulated doxorubicin (TLC D-99) and cyclophosphamide (CPA) vs. epirubicin (EPI) and CPA in first-line treatment of metastatic breast cancer (MBC)

European Journal of Cancer ◽

10.1016/s0959-8049(99)81679-7 ◽

1999 ◽

Vol 35 ◽

pp. S315 ◽

Cited By ~ 2

Author(s):

S. Chan ◽

N. Davidson ◽

E. Juozaityte ◽

F. Erdkamp ◽

L. Hooftman ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

First‐Line Treatment Patterns and Clinical Outcomes in Patients With HER2‐Positive and Hormone Receptor‐Positive Metastatic Breast Cancer From registHER

The Oncologist ◽

10.1634/theoncologist.2012-0414 ◽

2013 ◽

Vol 18 (5) ◽

pp. 501-510 ◽

Cited By ~ 37

Author(s):

Debu Tripathy ◽

Peter A. Kaufman ◽

Adam M. Brufsky ◽

Musa Mayer ◽

Marianne Ulcickas Yood ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽